Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Conditions
Interventions
VXA-RSV-f Tablets (high dose)
VXA Placebo Tablets
+1 more
Locations
1
United States
Optimal Research
Melbourne, Florida, United States
Start Date
June 22, 2016
Primary Completion Date
September 16, 2016
Completion Date
September 20, 2017
Last Updated
August 16, 2018
NCT05045612
NCT06998251
NCT06521944
NCT07249320
NCT04896853
NCT03756766
Lead Sponsor
Vaxart
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions